Petri Dishes

Recent News

November2018

aTen Therapeutics attends the BIA’s 15th Annual bioProcessUK Conference in Edinburgh, “Bioprocess Intensification – Driving down the cost of medicines”.

November 2018

aTen Therapeutics attends the Life Sciences Scotland conference in Glasgow, “Moving forward together: to 2025 and beyond”.

Overview

Our management team has extensive experience within the biopharmaceutical industry, and a wealth of knowledge in building successful biotechnology companies.

The team was responsible for the formation and subsequent growth of Bioenvision Inc. into a NASDAQ National listed, global biopharmaceutical company, which was acquired by Genzyme Corporation in October 2007.

This experienced management team is now applying its expertise to the growth of aTen Therapeutics and the development of Tensinomab as a new medicine with the potential to treat several serious medical conditions.

A subsidiary of OncoBioPharm Ltd, aTen Therapeutics has recently completed a financing round which will take lead candidate Tensinomab through to clinical trials.

info@atentherapeutics.com

© aTen Therapeutics 2018. All rights reserved